Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ZymoGenetics Experiences a Biotech Disconnect

This article was originally published in RPM Report

Executive Summary

It's logical to think that synthetic thrombin is safer than bovine- or plasma-derived equivalents. But ZymoGenetics is finding out it's not an easy sell, especially to Wall Street.

You may also be interested in...



Advertising Citations Reach Record High: Another Way To Regulate Pharma?

FDA's Division of Drug Marketing, Advertising and Communications has sent half of this year's citations for misleading advertising in the past month

Biologics Are Ray Of Light In Dim Outlook For FDA’s 2008 Approval Totals

At the half-year mark, FDA had approved eight novel BLAs – more than in all of 2007.

FDA Challenges ZymoGenetics' Safety Claims

Agency takes issue with part of the better-than-bovine thrombin boast.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS080419

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel